Pasithea Intangible Assets from 2010 to 2026
| KTTA Stock | USD 0.81 0.07 7.95% |
Intangible Assets | First Reported 2010-12-31 | Previous Quarter 6.6 M | Current Value 6.4 M | Quarterly Volatility 736.7 K |
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 783.7 K, Interest Expense of 224 or Other Operating Expenses of 10.4 M, as well as many indicators such as Price To Sales Ratio of 2.2 K, Dividend Yield of 0.0 or PTB Ratio of 0.26. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
Pasithea | Intangible Assets | Build AI portfolio with Pasithea Stock |
Analyzing Pasithea Therapeutics's Intangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Intangible Assets has evolved provides context for assessing Pasithea Therapeutics's current valuation and future prospects.
Latest Pasithea Therapeutics' Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of Pasithea Therapeutics Corp over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Pasithea Therapeutics' Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
Pasithea Intangible Assets Regression Statistics
| Arithmetic Mean | 8,212,633 | |
| Geometric Mean | 8,177,792 | |
| Coefficient Of Variation | 8.97 | |
| Mean Deviation | 548,821 | |
| Median | 8,571,478 | |
| Standard Deviation | 736,704 | |
| Sample Variance | 542.7B | |
| Range | 2.2M | |
| R-Value | (0.71) | |
| Mean Square Error | 285.2B | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | (103,922) | |
| Total Sum of Squares | 8.7T |
Pasithea Intangible Assets History
About Pasithea Therapeutics Financial Statements
Pasithea Therapeutics stakeholders use historical fundamental indicators, such as Pasithea Therapeutics' Intangible Assets, to determine how well the company is positioned to perform in the future. Although Pasithea Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pasithea Therapeutics' assets and liabilities are reflected in the revenues and expenses on Pasithea Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pasithea Therapeutics Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 6.6 M | 6.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out the analysis of Pasithea Therapeutics Correlation against competitors. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. Expected growth trajectory for Pasithea significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pasithea Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.43) | Revenue Per Share | Quarterly Revenue Growth 14.981 | Return On Assets | Return On Equity |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Pasithea Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Pasithea Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Pasithea Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.